AIM Disclosure

RNS Number : 5898H

Futura Medical PLC

16 March 2015

 



For immediate release

16 March 2015

Futura Medical plc

("Futura" or the "Company")

AIM Disclosure

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, has today been informed of the following disclosure in accordance with the requirements of Rule 17 (disclosure of miscellaneous information). On 16 March 2015, administrators were appointed to Hume Capital Securities plc, a company of which Jonathan Freeman, a Non-Executive Director of Futura, was a non-executive director since March 2012.

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell - Corporate Finance Brough Ransom - Sales	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Sophie Cowles / Stephanie Watson	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com   

 

END

 

 

MSCPKADQOBKDDND